<DOC>
	<DOCNO>NCT02808429</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , dose response efficacy atacicept patient IgA nephropathy persistent proteinuria . The study hypothesis treatment atacicept reduce proteinuria compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Atacicept IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Greater equal ( &gt; = ) 18 year age Biopsyproven Immunoglobulin ( IgA ) nephropathy Proteinuria 1 6 gram per day ( g/day ) Stable optimal dose Angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 8 week prior screen Concomitant significant renal disease IgA nephropathy IgA nephropathy significant glomerulosclerosis cortical scar Diagnosis HenochSchonlein purpura Failure meet estimate glomerular filtration rate ( eGFR ) biopsy requirement criterion Serum IgG 6 gram per liter ( g/L ) Use cyclophosphamide ever use immunosuppressant systemic corticosteroid within 4 month Active infection require hospitalization treatment parenteral antiinfectives within 4 week History , current diagnosis , active tuberculosis ( TB ) , untreated latent TB infection History positive HIV and/or positive hepatitis B Hepatitis C screen History malignancy Nursing pregnancy Any condition , include uncontrolled disease state IgA nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atacicept</keyword>
	<keyword>IgA Nephropathy</keyword>
	<keyword>BergerÂ´s disease</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Proteinuria</keyword>
</DOC>